MedPath

se of aromatherapy for anxiety and stress in the general community due to social isolation caused by the Covid-19 pandemic

Phase 2
Recruiting
Conditions
anxiety disorders
F06.4
Registration Number
RBR-5xp737h
Lead Sponsor
niversidade de Franca
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Participants must be over 18 years old and less than 60 years old; They must reside in the city for at least 12 months; Present internet access with a valid email address or a valid WhatsApp number. Present a score above 8 on the Depression, Anxiety and Stress Scale anxiety test and above 10 on the general test.

Exclusion Criteria

Age within 18 years or above 60 years; Not residing in Franca/SP; Use benzodiazepines in the last 30 days; Use non-selective monoamine reuptake inhibitors (Imipramine, Clomipramine, Amitriptyline, Nortriptyline) , Serotonin Reuptake Inhibitors and ALPHA-2 (alfa2) Antagonists (Nefazodone, Trazodone), Selective Dopamine Reuptake Inhibitors (Bupropion), ALPHA-2 (alfa2) Antagonists (Mirtazapine), Monoamine Oxidase Inhibitors (Tranylcypromine, Moclobemide); Not having high blood pressure. Not being pregnant.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
It is expected to find the anxiolytic potential of the aromatic blend developed for this purpose, from the identification of the DASS21 scale (Depression, Anxiety and Stress Scale), compared to the beginning. We also want to find a difference between the intervention group and the placebo control.
Secondary Outcome Measures
NameTimeMethod
It is expected to find the potential on sleep quality through the aromatic blend developed for this purpose compared to the beginning. It is also desired to find a difference between the intervention group and placebo control.
© Copyright 2025. All Rights Reserved by MedPath